Dermata Therapeutics

Ipsen SA formerly the Beaufour-Ipsen Group, is a European pharmaceutical group founded in 1929. The group's research and development is targeted to the disease areas of endocrinology, oncology and neuromuscular disorders.In April 2011, Ipsen SA was nearing to completing a strategic review and planned to announce details in June of that year. In June 2011, the company announced restructuring plans in which it would restructure its business into four market-based franchises and focus its R&D on its peptide and tocin-based technologies. The company also planned to merge its R&D departments and close its Barcelona, Spain R&D center.The company planned to create four franchises: Endocrinology/Somatuline (lanreotide depot); Neurology/Dysport (abobotulinumtoxinA); Uro-oncology/Decapeptyl (triptorelin pamoate); and Hemophilia. It also planned to maximize the value of its short stature business, and this was to be managed directly by regions and countries. Ipsen also intended to to grow its primary care

丹望医疗科技上海有限公司位于上海南翔精准医学产业园，致力于将最新的再生医学类器官技术临床转化，应用于疾病的诊疗、新药筛选、肿瘤标志物开发与鉴定，努力为临床提供个性化治疗的新技术，为新药研发提供精准、高效、优质的类器官模型。公司拥有全球领先的类器官技术创新平台，已建立了肺、胰腺、乳腺、胃、肠、肝等多个人体器官组织的类器官培养体系。

Ottimo Pharma是一家私营生物技术公司，由Medicxi和Jonny Finlay于2020年共同创立，专注于开发用于实体瘤的开创性创新癌症疗法。该公司的主导项目Jankistomig是一种PD1-VEGFR2双功能抗体，旨在通过单一IgG疗法同时靶向免疫检查点抑制和血管生成。通过推进这种双途径方法，Ottimo Pharma旨在改善癌症治疗结果，降低总体医疗负担。